GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spectrum Pharmaceuticals Inc (NAS:SPPI) » Definitions » PB Ratio

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) PB Ratio : 7.86 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Spectrum Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), Spectrum Pharmaceuticals's share price is $1.03. Spectrum Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2023 was $0.13. Hence, Spectrum Pharmaceuticals's PB Ratio of today is 7.86.

The historical rank and industry rank for Spectrum Pharmaceuticals's PB Ratio or its related term are showing as below:

SPPI' s PB Ratio Range Over the Past 10 Years
Min: 0.12   Med: 1.89   Max: 9.92
Current: 7.86

During the past 13 years, Spectrum Pharmaceuticals's highest PB Ratio was 9.92. The lowest was 0.12. And the median was 1.89.

SPPI's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.385 vs SPPI: 7.86

During the past 12 months, Spectrum Pharmaceuticals's average Book Value Per Share Growth Rate was -57.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -56.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -48.50% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -26.90% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Spectrum Pharmaceuticals was 115.90% per year. The lowest was -77.60% per year. And the median was -13.60% per year.

Back to Basics: PB Ratio


Spectrum Pharmaceuticals PB Ratio Historical Data

The historical data trend for Spectrum Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectrum Pharmaceuticals PB Ratio Chart

Spectrum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.56 2.17 3.71 4.39 2.69

Spectrum Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.17 4.31 2.44 2.69 5.73

Competitive Comparison of Spectrum Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Spectrum Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spectrum Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spectrum Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Spectrum Pharmaceuticals's PB Ratio falls into.



Spectrum Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Spectrum Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2023)
=1.03/0.131
=7.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Spectrum Pharmaceuticals  (NAS:SPPI) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Spectrum Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Spectrum Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Pilot House - Lewis Wharf, 2 Atlantic Avenue, 6th Floor, Boston, MA, USA, 02110
Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations. It has one segment that is focused exclusively on developing and marketing oncology and hematology drug products.
Executives
Juhyun Lim director 11500 S. EASTERN AVE., SUITE 220, HENDERSON NV 89052
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Brittany Bradrick director C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Nora Brennan officer: See Remarks C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Keith M Mcgahan officer: Chief Legal Officer 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Thomas J Riga director, officer: CEO & President 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Jeff L Vacirca director 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Francois Lebel officer: Chief Medical Officer 4100 LEXINGTO AVE N, ARDEN HILLS MN 55126-2998
Dolatrai Vyas director 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Kurt A Gustafson officer: EVP & Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Joseph W. Turgeon officer: Chief Commercial Officer 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Elizabeth Czerepak director 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Maida Anthony E Iii director 157 TECHNOLOGY DR, IRVINE CA 92618
Stuart Mitchell Krassner director 157 TEHCNOLOGY DRIVE, IRVINE CA 92618

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Headlines

From GuruFocus